Otonomy Analyst Ratings
Piper Sandler Downgrades Otonomy to Neutral From Overweight, Lowers Price Target to $0.50 From $3
Otonomy Cut to Neutral From Buy by HC Wainwright & Co.
Otonomy analyst ratings
Piper Sandler Adjusts Otonomy Price Target to $3 From $6, Maintains Overweight Rating
Analysts Offer Insights on Healthcare Companies: Veru (VERU), Otonomy (OTIC) and Karuna Therapeutics (KRTX)
No Data
No Data